Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.
Molecular therapy. Nucleic acids
View this publicationMolecular therapy. Nucleic acids
View this publicationScientific reports
View this publicationPublication categories: Top publication
Nature communications
View this publicationMolecular therapy. Nucleic acids
View this publicationPublication categories: Top publication
Nucleic acids research
View this publicationCell communication and signaling : CCS
View this publicationCell reports. Medicine
View this publicationClinical drug investigation
View this publicationVaccines
View this publicationEMBO molecular medicine
View this publication